Pegvaliase

Drug Profile

Pegvaliase

Alternative Names: BMN-165; PEG-PAL; Pegylated recombinant Anabaena variabilis phenylalanine ammonia lyase; PEGylated recombinant phenylalanine ammonia lyase; Phenylase; rAvPAL-PEG

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBEX Technologies
  • Developer BioMarin Pharmaceutical
  • Class Ammonia lyases; Enzymes; Recombinant proteins
  • Mechanism of Action Phenylalanine ammonia lyase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Phenylketonuria

Most Recent Events

  • 14 Sep 2017 US FDA is not planning to hold advisory committee meeting for the review of BLA of pegvaliase for Phenylketonuria
  • 30 Aug 2017 FDA assigns PDUFA action date of (28/02/2018) for pegvaliase for Phenylketonuria
  • 30 Aug 2017 Pegvaliase receives priority review status for Phenylketonuria in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top